Quantum Genomics SA (ALQGC) - Total Liabilities
Based on the latest financial reports, Quantum Genomics SA (ALQGC) has total liabilities worth €2.81 Million EUR (≈ $3.29 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Quantum Genomics SA cash flow conversion to assess how effectively this company generates cash.
Quantum Genomics SA - Total Liabilities Trend (2009–2024)
This chart illustrates how Quantum Genomics SA's total liabilities have evolved over time, based on quarterly financial data. Check ALQGC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quantum Genomics SA Competitors by Total Liabilities
The table below lists competitors of Quantum Genomics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Throgmorton Trust Plc
LSE:THRG
|
UK | GBX6.49 Million |
|
Dimet (Siam) Public Company Limited
BK:DIMET
|
Thailand | ฿147.09 Million |
|
E-Pango SA
PA:ALAGO
|
France | €4.20 Million |
|
SIV Capital Ltd
AU:SIV
|
Australia | AU$113.58K |
|
Nala Digital Commerce Ltd
TA:SEFA
|
Israel | ILA10.28 Million |
|
Freehill Mining Ltd
AU:FHS
|
Australia | AU$800.01K |
Liability Composition Analysis (2009–2024)
This chart breaks down Quantum Genomics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Quantum Genomics SA (ALQGC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum Genomics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum Genomics SA (2009–2024)
The table below shows the annual total liabilities of Quantum Genomics SA from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.81 Million ≈ $3.29 Million |
-15.09% |
| 2023-12-31 | €3.31 Million ≈ $3.87 Million |
-83.49% |
| 2022-12-31 | €20.05 Million ≈ $23.44 Million |
+73.22% |
| 2021-12-31 | €11.57 Million ≈ $13.53 Million |
+42.06% |
| 2020-12-31 | €8.15 Million ≈ $9.53 Million |
+51.65% |
| 2019-12-31 | €5.37 Million ≈ $6.28 Million |
-18.75% |
| 2018-12-31 | €6.61 Million ≈ $7.73 Million |
+31.06% |
| 2017-12-31 | €5.05 Million ≈ $5.90 Million |
+85.70% |
| 2016-12-31 | €2.72 Million ≈ $3.18 Million |
+7.89% |
| 2015-12-31 | €2.52 Million ≈ $2.94 Million |
-48.42% |
| 2014-12-31 | €4.88 Million ≈ $5.71 Million |
+47.01% |
| 2013-12-31 | €3.32 Million ≈ $3.88 Million |
+68.19% |
| 2012-12-31 | €1.97 Million ≈ $2.31 Million |
+278.97% |
| 2011-12-31 | €521.06K ≈ $609.18K |
-35.26% |
| 2010-12-31 | €804.81K ≈ $940.91K |
+50.48% |
| 2009-12-31 | €534.82K ≈ $625.26K |
-- |
About Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.